Understanding The Potential Role of CCNI2 in Cell Cycle Progression
Understanding The Potential Role of CCNI2 in Cell Cycle Progression
Cyclin I family member 2 (CCNI2) is a protein that is expressed in a variety of tissues throughout the body. It is a key component of the cyclin D1-CDK4 complex, which is involved in cell cycle progression and division. Despite its importance, little is known about CCNI2 and its potential role in human disease. In this article, we will explore the biology of CCNI2 and its potential as a drug target.
The Cyclin D1-CDK4 Complex
The cyclin D1-CDK4 complex is a critical regulatory complex that is involved in the control of cell cycle progression. It consists of five subunits: CDK4, CDK6, p21, p22, and p23. CDK4 and CDK6 are the core subunits, and they play a key role in regulating the activity of the complex. p21 and p22 are middle subunits that play a critical role in regulating the stability of the complex, while p23 is the least well-studied subunit.
CCNI2 is a key component of the cyclin D1-CDK4 complex. It is a 21-kDa protein that is expressed in a variety of tissues, including muscle, heart, brain, and liver. It is highly conserved, with a calculated pI of 18.9 nM and a predicted localization in the cytoplasm.
CCNI2's Role in Cell Cycle Progression
CCNI2 is involved in the regulation of cell cycle progression by the cyclin D1-CDK4 complex. It plays a key role in regulating the activity of the complex by interacting with CDK4 and CDK6. Studies have shown that CCNI2 can interact with CDK4 and CDK6 and regulate their activity.
One of the most significant functions of CCNI2 is its ability to regulate the activity of CDK4 and CDK6. Studies have shown that CCNI2 can inhibit the activity of CDK4 and CDK6 and regulate the rate of cell cycle progression. This can lead to the accumulation of chromosomes in the G1 phase and the inhibition of G2 and M phases.
In addition to regulating the activity of CDK4 and CDK6, CCNI2 is also involved in the regulation of the cytoskeleton. Studies have shown that CCNI2 can interact with the cytoskeleton and regulate the stability of the cell. This can lead to the accumulation of chromosomes in the G1 phase and the inhibition of G2 and M phases.
Potential Drug Targets
Despite its importance in cell cycle regulation, little is known about CCNI2 and its potential as a drug target. However, studies have shown that CCNI2 is a potential drug target due to its unique biology and the involvement of the cyclin D1-CDK4 complex.
One potential drug target for CCNI2 is the inhibition of its activity. This can be achieved through the use of small molecules or antibodies that specifically target CCNI2. Studies have shown that inhibitors of CCNI2 can inhibit the activity of CDK4 and CDK6 and regulate the rate of cell cycle progression.
Another potential drug target for CCNI2 is the modulation of its expression. This can be achieved through the use of drugs that modify the expression of CCNI2 or through the use of techniques such as RNA interference or CRISPR/Cas9. Studies have shown that modulation of CCNI2 expression can have a significant impact on the activity of the cyclin D1-CDK4 complex.
Conclusion
In conclusion, CCNI2 is a protein that is involved in the regulation of cell cycle progression and is a potential drug target. Its unique biology and the involvement of the cyclin D1-CDK4 complex make it an attractive target for research and development. Further studies are needed to fully understand the role of CCNI2 in
Protein Name: Cyclin I Family Member 2
The "CCNI2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNI2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG
